{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '11.3.', 'International Society on Thrombosis and Hemostasis Guideline for', 'Assessment of Treatment Response', 'ISTH recommendations [12] are provided in the table below for assessment of treatment', 'response (Table 11).', 'Table 11:', 'Assessment of Treatment of Acute Joint/Muscle Bleeding Episodes', 'Category', 'Response', 'Excellent', 'Complete pain relief within 8 hours and/or complete resolution of signs of bleeding', 'after the initial injection and not requiring any further replacement therapy for relief', 'of persistent symptoms and signs in the same joint within 72 hours', 'Good', 'Significant pain relief and/or improvement in signs of bleeding within', 'approximately 8 hours after a single injection, but requiring more than one dose of', 'replacement therapy within 72 hours for complete resolution', 'Moderate', 'Modest pain relief and/or improvement in signs of bleeding within approximately', '8 hours after the initial injection and requiring more than one injection within', '72 hours but without complete resolution', 'None', 'No or minimal improvement, or condition worsens, within approximately 8 hours', 'after the initial injection', '11.4.', 'Bleed Severity Definitions', 'The definitions of bleed severity are shown in Table 12.', 'Table 12:', 'Bleed Severity Definitions', 'Bleed Severity', 'Definition', 'Minor', 'Early joint bleeding; mild muscle bleeding; or mild bleeding (any other', 'location)', 'Moderate', 'Definite joint bleeding; moderate muscle bleeding; moderate bleeding', '(any other location); known trauma (other than head trauma or fractures)', 'Major', 'Severe bleeding that is life- or limb-threatening; including fractures and', 'head trauma', '11.5.', 'Country-Specific Requirements', 'Country-specific requirements are provided in separate country-specific protocol.', 'Property of the Sanofi Group - strictly confidential', '80']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '11.6.', 'Protocol Amendment History', 'The Protocol Amendment Summary of Changes Table for the current amendment is located', 'directly before the Table of Contents (TOC).', '11.6.1.', 'Amended Protocol 01', 'Primary changes:', 'Updated clinical development status text to account for a patient death, which was', 'reported in a patient with cerebral venous sinus thrombosis (CVST) in the', 'ALN-AT3SC-002 study (Phase 1/2 open-label extension study)', 'Additional safety measures were implemented to mitigate risk of thrombosis in the', 'lowered-AT setting, including: revised bleed management guidelines to allow standard', 'BPA regimens only up to the first 7 days following fitusiran dosing; added', 'recommendations for monitoring and management of thrombotic events; added', 'clarification of definitions for bleeding episodes; revised recommendations for', 'management of sepsis, and adding additional exploratory laboratory assessments', 'Frequency of directed physical exams to monthly', 'Updated Benefit-Risk Assessment section accordingly with respect to the above new', 'safety monitoring', 'Added Patient Education Module training to Schedule of Assessments', 'Clarification added that Adverse Events should include review for signs and symptoms of', 'thrombosis at each visit', 'Clarifications added to the Perioperative Schedule of Assessments', 'Addition of acetaminophen restriction to <4 grams per day', 'Stipulation added that antifibrinolytics may be used as single agents, but may not be used', 'in combination with factor or BPA', 'Addition that aPCC and rFVIIa are not recommended for use as combination therapy', 'Revised bleed management recommendations following discontinuation of fitusiran;', 'standard on-demand dosing with BPAs is permitted when AT residual activity level', 'returns to ~60% (per the central laboratory)', 'Addition of prothrombin activation fragment 1,2 to the coagulation panel, as exploratory', 'marker of hemostasis', 'Addition of new stipulation for patients who present to the study site for management of', 'bleed symptoms, samples will be collected pre-treatment and post-treatment with factor', 'or BPA for the exploratory purposes of characterizing thrombin generation and other', 'coagulation parameters', 'Other minor corrections applied.', 'Property of the Sanofi Group - strictly confidential', '81']\n\n###\n\n", "completion": "END"}